EUCTR2012-001781-15-ES
Active, not recruiting
Not Applicable
Initial protocol setting for the treatment of choroidal neovascularization associated to myopia magna with intravitreal bevacizumab: 3 vs 1 (BENEMCOR.es study) - BENEMCOR.es
IOBA, Universidad de Valladolid0 sitesMay 29, 2012
DrugsAvastin® 25 mg/ml
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- IOBA, Universidad de Valladolid
- Status
- Active, not recruiting
- Last Updated
- 13 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\-Myopic patients over 18 years with active subfoveal choroidal neovascularisation associated to yuxtafoveolar myopia confirmed by AGF and OCT.
- •2\-Patients with loss of visual acuity less than 6 months lenght caused by the neovascular lesion at the discretion of the researcher.
- •3\-Lesions in which the presence of atrophic or fibrotic component does not prevent vision improvement .
- •4\-4\-Patients with active subfoveal and yuxtafoveolar choroidal neovascularization associated with myopia magna previously treated with photodynamic therapy.
- •5\-Informed written consent.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1\.2 Adults (18\-64 years) yes
- •F.1\.2\.1 Number of subjects for this age range 100
- •F.1\.3 Elderly (\>\=65 years) yes
Exclusion Criteria
- •1\-Previous surgery vitrectomy.
- •2\-tractional maculopathy and/or idiopathic epiretinal membrane diagnosed by OCT.
- •3\-media opacity that does not allow to adequately assess the fundus of the eye.
- •4\-Lack of integrity of the posterior lens capsule in pseudophakia.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Not yet recruiting
Not Applicable
Work Injury Screening and Early intervention (WISE) StudyWork related soft tissue injuriesMusculoskeletal - Other muscular and skeletal disordersACTRN12613000847718Sydney Medical School (Northern) - University of Sydney220
Not yet recruiting
Phase 1
Clinical study protocol for the treatment of moderate to severe persistent allergic rhinitis with lung-deficiency-related cold type by fire acupuncture at the Inner Yingxiang(Ex-HN09) pointITMCTR2200006073Beijing Hospital of Traditional Chinese Medicine, Capital Medical University
Active, not recruiting
Not Applicable
A Treatment Protocol for Patients Continuing from a Prior SU011248 ProtocolThis is an open-label treatment protocol for patients who have participated in other SU011248 protocols to completion and are believed to have the potential to derive clinical benefit from SU011248 treatment. Included in this protocol will be patients assigned to placebo in a previous study who did not qualify for crossover within the original protocol due to declining health status (eg, performance status lower than crossover eligibility criterionMedDRA version: 7.1Level: LLYClassification code 10062427EUCTR2004-001093-11-SEPfizer Ltd
Active, not recruiting
Not Applicable
A Treatment Protocol for Patients Continuing from Prior SU0011248 ProtocolGastrointestinal stromal tumorEUCTR2004-001093-11-ESPfizer SA
Active, not recruiting
Phase 1
A Treatment Protocol for Patients Continuing from a Prior SU011248 ProtocolThis is an open-label treatment protocol for patients who have participated in other SU011248 protocols to completion and are believed to have the potential to derive clinical benefit from SU011248 treatment. Included in this protocol will be patients assigned to placebo in a previous study who did not qualify for crossover within the original protocol due to declining health status (eg, performance status lower than crossover eligibility criterionMedDRA version: 7.1 Level: LLY Classification code 10062427EUCTR2004-001093-11-GBPfizer Global Research and Development